Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) EBITDA Margin (2020 - 2021)

Rapid Therapeutic Science Laboratories' EBITDA Margin history spans 2 years, with the latest figure at 1045400.0% for Q4 2021.

  • For Q4 2021, EBITDA Margin changed N/A year-over-year to 1045400.0%; the TTM value through Sep 2022 reached 3196525.0%, down 322029519.0%, while the annual FY2021 figure was 407471.54%, 40594834.0% down from the prior year.
  • EBITDA Margin for Q4 2021 was 1045400.0% at Rapid Therapeutic Science Laboratories, down from 992262.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 386.99% in Q1 2020 and bottomed at 1045400.0% in Q4 2021.